Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension
A Takeda and ARCH-backed startup looking to prove out the next potential RNA goldmine in drug R&D has secured more capital en route to a 2024 clinical entry, CEO Leslie Williams tells Endpoints News.
The biotech, hC Bioscience, almost never came to be. Williams was set to climb Mount Everest in 2020. But the Covid-19 pandemic had other plans, so the veteran biotech CEO had time to go full throttle on engaging the lab at the University of Iowa that produced a 2019 paper in Nature Communications and then secure the IP, gather feedback from scientists and then form a story to tell investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.